Gregg Gilbert
Stock Analyst at Truist Securities
(2.28)
# 2,621
Out of 4,944 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.25 | +51.11% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $37.87 | -2.30% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $46.55 | +80.45% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $639.43 | -17.90% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.40 | +103.13% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $11.34 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $80.30 | +15.82% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $14.74 | +225.64% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $0.92 | +2,738.74% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.48 | +10,035.14% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $23.07 | +238.10% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $149.77 | -47.92% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $16.60 | +8.43% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $113.33 | +54.42% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $198.64 | -66.77% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.25
Upside: +51.11%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $37.87
Upside: -2.30%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $46.55
Upside: +80.45%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $639.43
Upside: -17.90%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.40
Upside: +103.13%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $11.34
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $80.30
Upside: +15.82%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $14.74
Upside: +225.64%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $0.92
Upside: +2,738.74%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.48
Upside: +10,035.14%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $23.07
Upside: +238.10%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $149.77
Upside: -47.92%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $16.60
Upside: +8.43%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $113.33
Upside: +54.42%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $198.64
Upside: -66.77%